CL
ALLO icon

Choreo LLC’s Allogene Therapeutics ALLO Stock Holding History

Choreo LLC’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$260K Sell
125,062
-17,587
-12% -$38.6K ﹤0.01% 1397
2026
Q1 		$348K Buy
142,649
+103,800
+267% +$208K ﹤0.01% 1159
2025
Q4 		$50.9K Buy
+38,849
New +$51.2K ﹤0.01% 1534

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Choreo LLC's ALLO Position: Q2 2026 in Review

Choreo LLC reduced its Allogene Therapeutics (ALLO) stake by 12% in Q2 2026, selling an estimated $38.6K and leaving 125,062 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #1397.

Choreo LLC first reported a position in ALLO in Q4 2025 and has held it in 3 quarters since. The position peaked at $348K in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Choreo LLC held 125,062 shares of Allogene Therapeutics worth $260K as of Q2 2026.
  • Choreo LLC sold 17,587 Allogene Therapeutics shares in Q2 2026, an estimated $38.6K.
  • Allogene Therapeutics made up ﹤0.01% of Choreo LLC's portfolio in Q2 2026, its #1397 holding.
  • Choreo LLC first reported a position in Allogene Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Choreo LLC's Allogene Therapeutics position peaked at $348K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Choreo LLC's 13F filing for Q2 2026, filed 4 Aug 2026.